Prescription Drug Price Transparency
Announcements

MDH shares recent information related to the Prescription Drug Price Transparency Act's implementation on this page. 

MDH invites your ideas or suggestions for prescription drugs on which to collect data. Visit Public Input for information on how to provide feedback.

Sign up for email updates to receive news and notifications.

MDH shares updated technical assistance to the Minnesota Prescription Drug Affordability Board (MN PDAB)

As part of MDH's technical assistance to the MN PDAB, MDH released an updated list of drugs that met the criteria established in Minnesota Statutes 62J.90, subdivision 2 in the past year. This updated list of over 1,100 drugs that met statutory criteria is available on the Technical Assistance to the MN PDAB webpage. 

Updated data

June 1, 2026

The Minnesota Department of Health (MDH) has released new data contained in online data dashboards and downloadable files for the Minnesota Prescription Drug Price Transparency initiative. Visit Data and Dashboards to access the interactive and downloadable files.

Now open: Reporting on April 2026 list of Drugs of Substantial Public Interest

May 18, 2026

Reporting is now open in the Rx Data Portal for the newest list of Drugs of Substantial Public Interest. Visit the Drugs of Substantial Public Interest Lists webpage for details. MDH sent notifications to entities registered in the Portal on 5/18/2026. Reports are due 60 days later, 7/17/2026. The date range for data this reporting period is 1/1/2025 through 12/31/2025.

MDH releases 2026 Report to the Minnesota Legislature

April 17, 2026

MDH released the Minnesota Prescription Drug Transparency: 2026 Report to the Minnesota Legislature (PDF). It presents analysis of information reported to MDH through the first half of 2025 and assesses the Act’s progress toward statutory goals. 

April 2026 List of Drugs of Substantial Public Interest posted

April 13, 2026

MDH has posted the April 2026 List of Drugs of Substantial Public Interest. This list is based on the first group of drugs selected for negotiation under the Medicare Drug Price Negotiation Program, which was authorized as part of the Inflation Reduction Act of 2022. To view the list and accompanying methodology, visit Drugs of Substantial Public Interest Lists.

Manufacturers, pharmacies, wholesalers, and PBMs with a reporting obligation will be notified of the need to report no sooner than 30 days after this release and will have 60 days after the date of notification to report. Reporting guidance and supporting materials are available on Reporting Resources. 

Updated data

December 2, 2025

The Minnesota Department of Health (MDH) has released new data contained in online data dashboards and downloadable files for the Minnesota Prescription Drug Price Transparency initiative. Visit RxPT Data and Dashboards to access the interactive and downloadable files.